$3.25
-0.01 (-0.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XBIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 1 with posted results
Held by 1 tracked-famous manager (RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial CancerNCT03077698results2022-06-07Overall Disease Control (ODC) as Determined by Radiographic Imaging MeasurementsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was discontinued due to a change in development strategy and not due safety concern. | Drug: Sodium Cridanimod, progestin therapy | Endometrial Cancer | 25 | 2020-07-17actual | 2022-06-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19